Synergy Pharmaceuticals Inc (SGYP) Drops 5.29% on January 28

Equities Staff |

Synergy Pharmaceuticals Inc (SGYP) was one of the Russell 2000's biggest losers for Thursday January 28 as the stock slid 5.29% to $3.58, a loss of $-0.2 per share. Starting at an opening price of $3.87 a share, the stock traded between $3.56 and $3.91 over the course of the trading day. Volume was 1.79 million shares over 8,927 trades, against an average daily volume of 2.26 million shares and a total float of 113.67 million.

The losses send Synergy Pharmaceuticals Inc down to a market cap of $406.95 million. In the last year, Synergy Pharmaceuticals Inc has traded between $10.15 and $2.84, and its 50-day SMA is currently $5.41 and 200-day SMA is $6.14.

Synergy Pharmaceuticals Inc is a biopharmaceutical company. It engages in the development of drugs to treat gastrointestinal, or GI, disorders and diseases.

Synergy Pharmaceuticals Inc is based out of New York, NY and has some 35 employees. Its CEO is Gary S. Jacob.

For a complete fundamental analysis analysis of Synergy Pharmaceuticals Inc, check out’s Stock Valuation Analysis report for SGYP. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth


VOIP-PAL COM Inc is a development stage company. The Company is engaged in broadband Voice-over-Internet Protocol ("VoIP") market with the ownership and continuing development of a portfolio of VoIP Patents.

Private Markets

BioSculpture Technology, Inc.

BioSculpture Technology, Inc. (“BST”) is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction ("TCAL") Airbrush Liposculptor II® controllers, Airbrush®…


Lyft matches drivers using their own personal vehicles with passengers who request rides through the smartphone app, and the passengers pay automatically through the app. When using Lyft, passengers have…